Lumos Diagnostics (LDX) Stock Price, News & Analysis

Company Overview

Lumos Diagnostics Holdings Limited, a contract research and development company, develops, manufactures, and commercializes rapid point-of-care (POC) diagnostic products for diagnosis and management of infectious diseases in the United States and Australia. The company's products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$14.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

LDX Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Lumos Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Lumos Diagnostics investors own include T2 Biosystems (TTOO), GT Biopharma (GTBP) and Aditxt (ADTX).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Diagnostics & Research
• Sub-Industry: Banking
• Current Symbol: ASX:LDX
• CIK: N/A
• Web: lumosdiagnostics.com
• Phone: 61 3 9692 7222
• Fax: N/A
• Employees: 217,000
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$8.59 million
• Net Margins: -77.19%
• Pretax Margin: N/A
• Return on Equity: -105.19%
• Return on Assets: -18.32%

Debt

• Debt-to-Equity Ratio: 113.38
• Current Ratio: 0.76
• Quick Ratio: 0.77

Sales & Book Value

• Annual Sales: A$11.13 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.01 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 562,990,000
• Free Float: N/A
• Market Cap: A$14.13 million
• Optionable: Not Optionable
• Beta: 0.78